keyword
MENU ▼
Read by QxMD icon Read
search

classical hodgkin lymphoma

keyword
https://www.readbyqxmd.com/read/28937385/primary-classical-hodgkin-lymphoma-of-rectum-report-of-an-extremely-rare-case-and-review-of-the-literature
#1
Jayasudha Arundhathi Vasudevan, Rekha A Nair, K Rakul Nambiar
Hodgkin lymphoma (HL) commonly presents as nodal disease, but in a subset of cases, the disease primarily develops in extranodal sites. Primary classical HL of the gastrointestinal (GI) tract is an extremely rare occurrence. Primary nature of the disease is confirmed after a complete lymphoma work up including chest radiograph, computed tomography scan, peripheral blood, and bone marrow studies. Only a few cases of primary GI lymphomas with limited immunohistochemical or molecular confirmation have been reported in literature...
July 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28937369/study-of-association-of-epstein-barr-virus-in-lymphomas-by-epstein-barr-virus-encoded-rna-in-situ-hybridization-an-indian-perspective-from-a-tertiary-care-cancer-institute
#2
Roshani Gala, Jatin S Gandhi, Gurudutt Gupta, Shrruti K Grover, Anila Sharma, Sunil Pasricha, Anurag Mehta
BACKGROUND: The Epstein-Barr virus (EBV), also called human herpesvirus 4, is a virus of the herpes family. The EBV-associated lymphomas include Burkitt lymphoma, classic Hodgkin lymphoma (HL), lymphomas arising in immunocompromised individuals, peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphoma, extranodal nasal-type natural killer/T-cell lymphoma, and other rare histotypes. OBJECTIVE: The present study evaluated the role of EBV as an etiologic agent in various lymphomas and determined an Indian perspective in a tertiary care cancer center compared to that of Western literature...
July 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28927453/employment-status-and-health-related-quality-of-life-among-hodgkin-lymphoma-survivors-results-based-on-data-from-a-major-treatment-center-in-hungary
#3
Ferenc Magyari, Karolina Kósa, Roland Berecz, Anna Illés, Zsófia Miltényi, Zsófia Simon, Árpád Illés
BACKGROUND: Due to risk and response adapted treatment strategies, more than 80% of newly diagnosed classical Hodgkin lymphoma (HL) patients can be cured, and become long-term survivors. However, a high proportion of survivors suffer from treatment-related long-term side effects such as secondary malignancy, organ failure, persistent fatigue and psychological distress. The aim of this study was to evaluate psychological distress and its risk factors among our HL survivors. METHODS: One hundred sixty-three (50% female) adult HL survivors were contacted between January 1, 2012 and march 31, 2015 in our outpatient centre...
September 19, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28923211/nivolumab-and-pembrolizumab-monoclonal-antibodies-against-programmed-cell-death-1-pd-1-that-are-interchangeable
#4
REVIEW
Vinay Prasad, Victoria Kaestner
Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance. These drugs have earned a series of FDA approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin lymphoma, and renal cell cancer...
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28921451/distribution-of-malignant-lymphomas-in-the-anterior-mediastinum-a-single-institution-study-of-76-cases-in-japan-1997-2016
#5
Akiko Miyagi Maeshima, Hirokazu Taniguchi, Tomotaka Suzuki, Sayako Yuda, Kosuke Toyoda, Nobuhiko Yamauchi, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Dai Maruyama, Yukio Kobayashi, Kensei Tobinai
We analyzed the distribution of tumors and lymphomas of the anterior mediastinum diagnosed between 1997 and 2016 at the National Cancer Center Hospital, Japan. The median age of 283 patients with anterior mediastinal tumors was 48 (range 6-84) years, and 143 (51%) were male. The incidence of tumors was as follows: thymoma, 34%; thymic carcinoma, 16%; primary mediastinal large B-cell lymphoma (PMBL), 13%; germ cell tumors, 10%; classical Hodgkin lymphoma (CHL), 9%; thymic cyst, 7%; metastatic tumors, 3%; T lymphoblastic leukemia/lymphoma (T-LBL), 2%; other lymphomas, 3%; and others, 3%...
September 18, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28919770/swollen-lymph-nodes-may-not-be-clinical-manifestations-of-chronic-myeloid-leukemia-case-report-and-revision-of-literature
#6
Zhihe Liu, Siyun Li, Ou Bai
We present here the case of a 33-year-old Chinese female patient with synchronous double primary malignant tumors (chronic myeloid leukemia [CML] and classic Hodgkin lymphoma). This patient was admitted to our hospital because of bilateral cervical lymph node enlargement and recurrent fever for 2 weeks. The complete blood cell count revealed white blood cell counts of 18.2×10(9)/L, hemoglobin of 9.6 g/dL, and platelet counts of 1,547×10(9)/L. Chromosome karyotype analysis demonstrated that t(9;22)(q34;q11) was positive in all 20 cells examined...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28910870/-primary-mediastinal-large-b-cell-lymphoma-a-clinicopathologic-study-of-27-cases
#7
Q Y Shi, X Feng, H Chen, H H Ma, Z F Lu, Q L Shi, X J Zhou, Q Shen
Objective: To study the clinicopathologic characteristics and diagnostic criteria of primary mediastinal B-cell lymphoma (PMBL), and to distinguish PMBL from classic Hodgkin lymphoma(CHL) and systemic diffuse large B-cell lymphoma(DLBCL). Methods: The clinical features, histologic findings, results of immunohistochemical study and prgnosis in 27 PMBL cases were analyzed, with review of literature. Results: The age of patients ranged from 19 to 82 years (median age 34 years). All cases were located in the mediastinum and frequently accompanied by superior vein cava syndrome...
September 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28899972/facts-and-hopes-in-immunotherapy-of-lymphoma-and-myeloma
#8
Matthew J Pianko, Alison J Moskowitz, Alexander M Lesokhin
Immune checkpoint blockade has driven a revolution in modern oncology, and robust drug development of immune checkpoint inhibitors is underway in both solid tumors and hematologic malignancies. High response rates to programmed cell death 1 (PD-1) blockade using nivolumab or pembrolizumab in classical Hodgkin lymphoma (cHL) and several variants of non-Hodgkin lymphoma (NHL) revealed an intrinsic biologic sensitivity to this approach, and work is ongoing exploring combinations with immune checkpoint inhibitors in both cHL and NHL...
September 12, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28898161/prognostic-model-to-predict-post-autologous-stem-cell-transplantation-outcomes-in-classical-hodgkin-lymphoma
#9
Fong Chun Chan, Anja Mottok, Alina S Gerrie, Maryse Power, Marcel Nijland, Arjan Diepstra, Anke van den Berg, Peter Kamper, Francesco d'Amore, Alexander Lindholm d'Amore, Stephen Hamilton-Dutoit, Kerry J Savage, Sohrab P Shah, Joseph M Connors, Randy D Gascoyne, David W Scott, Christian Steidl
Purpose Our aim was to capture the biology of classical Hodgkin lymphoma (cHL) at the time of relapse and discover novel and robust biomarkers that predict outcomes after autologous stem-cell transplantation (ASCT). Materials and Methods We performed digital gene expression profiling on a cohort of 245 formalin-fixed, paraffin-embedded tumor specimens from 174 patients with cHL, including 71 with biopsies taken at both primary diagnosis and relapse, to investigate temporal gene expression differences and associations with post-ASCT outcomes...
September 12, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28893733/topological-analysis-reveals-a-pd-l1-associated-microenvironmental-niche-for-reed-sternberg-cells-in-hodgkin-lymphoma
#10
Christopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, Margaretha G M Roemer, Edward C Stack, Evisa Gjini, Xihao Hu, Robert Redd, Gordon J Freeman, Donna Neuberg, F Stephen Hodi, Xiaole Shirley Liu, Margaret A Shipp, Scott J Rodig
Signaling between programmed cell death protein 1 (PD-1) and the programmed cell death -1 ligands (PD-1 ligands, PD-L1, PD-L2) is essential for malignant Hodgkin Reed-Sternberg (HRS) cells to evade anti-tumor immunity in classical Hodgkin lymphoma (cHL). Copy number alterations of 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) contribute to robust PD-L1 and PD-L2 expression by HRS cells. PD-L1 is also expressed by non-malignant tumor-associated macrophages (TAMs) but the relationships between PD-L1+ HRS cells, PD-L1+ TAMs, and PD-1+ T-cells remain undefined...
September 11, 2017: Blood
https://www.readbyqxmd.com/read/28878352/s1pr1-drives-a-feed-forward-signalling-loop-to-regulate-batf3-and-the-transcriptional-programme-of-hodgkin-lymphoma-cells
#11
K Vrzalikova, M Ibrahim, M Vockerodt, T Perry, S Margielewska, L Lupino, E Nagy, E Soilleux, D Liebelt, R Hollows, A Last, G Reynolds, M Abdullah, H Curley, M Care, D Krappmann, R Tooze, J Allegood, S Spiegel, W Wei, C B J Woodman, P G Murray
The Hodgkin/Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (HL) are characterised by the aberrant activation of multiple signalling pathways. Here we show that a subset of HL displays altered expression of sphingosine-1-phosphate (S1P) receptors (S1PR). S1P activates phosphatidylinositide 3-kinase (PI3-K) in these cells that is mediated by the increased expression of S1PR1 and the decreased expression of S1PR2. We also showed that genes regulated by PI3-K signalling pathway in HL cell lines significantly overlap with the transcriptional programme of primary HRS cells...
September 7, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28877074/gata3-immunohistochemical-staining-in-hodgkin-lymphoma-diagnostic-utility-in-differentiating-classic-hodgkin-lymphoma-from-nodular-lymphocyte-predominant-hodgkin-lymphoma-and-other-mimicking-entities
#12
Brie Kezlarian, Mohammad Alhyari, Girish Venkataraman, Kristin Karner, Kedar V Inamdar, Madhu P Menon
BACKGROUND: Classic Hodgkin lymphoma (CHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) are clinically distinct entities, with different prognostic and treatment implications. In addition, several large B-cell lymphomas and some T-cell lymphomas can mimic CHL. Differentiating these entities from CHL is crucial for ensuring appropriate therapy. GATA3 is a T-cell transcription factor involved in T-cell maturation and has been previously shown to be overexpressed in CHL cells via gene expression profiling...
September 4, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28857136/results-of-a-multicentre-uk-wide-retrospective-study-evaluating-the-efficacy-of-brentuximab-vedotin-in-relapsed-refractory-classical-hodgkin-lymphoma-in-the-transplant-naive-setting
#13
Toby A Eyre, Elizabeth H Phillips, Kim M Linton, Shireen Kassam, Adam Gibb, Suzanne Allibone, John Radford, Karl Peggs, Cathy Burton, Gillian Stewart, Rifca LeDieu, Catherine Booth, Wendy L Osborne, Fiona Miall, David W Eyre, Kirit M Ardeshna, Graham P Collins
Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-naïve relapsed/refractory cHL. All had received 2 prior lines and were deemed fit for transplant but had an insufficient remission to proceed...
August 31, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28851661/j-chain-and-myocyte-enhancer-factor-2b-are-useful-in-differentiating-classical-hodgkin-lymphoma-from-nodular-lymphocyte-predominant-hodgkin-lymphoma-and-primary-mediastinal-large-b-cell-lymphoma
#14
Erika M Moore, Steven H Swerdlow, Sarah E Gibson
Although most classical Hodgkin lymphomas (CHL) are easily distinguished from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and primary mediastinal large B-cell lymphoma (PMBL), cases with significant CD20 expression cause diagnostic confusion. Although the absence of OCT-2 and BOB.1 are useful in these circumstances, a variable proportion of CHL are positive for these antigens. We investigated the utility of J chain and MEF2B in the diagnosis of CHL, NLPHL, PMBL, T-cell/histiocyte-rich large B-cell lymphoma (TCRLBL), and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL (BCLU, DLBCL/CHL) compared to OCT-2 and BOB...
August 26, 2017: Human Pathology
https://www.readbyqxmd.com/read/28842748/pd-l1-expression-correlates-with-vegf-and-microvessel-density-in-patients-with-uniformly-treated-classical-hodgkin-lymphoma
#15
Young Wha Koh, Jae-Ho Han, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh
Recent studies have reported the associations between programmed death-ligand 1 (PD-L1) or PD-L2/PD-1 pathways and pro-angiogenic genes including hypoxia-inducible factors (HIFs) and vascular endothelial growth factor (VEGF) in several malignancies. However, no study has examined the relationship or prognostic implication of PD-L1, PD-L2, PD-1, VEGF expression, and microvessel density (MVD) in classical Hodgkin lymphoma (cHL) patients. Diagnostic tissues from 109 patients with doxorubicin, bleomycin, vinblastine, and dacarbazine-treated cHL were evaluated retrospectively by immunohistochemical analysis for PD-L1, PD-L2, PD-1, VEGF expression, and for CD31 expression as a measure of MVD...
August 25, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28832956/early-stage-hodgkin-lymphoma-outcomes-after-combined-modality-therapy-according-to-the-post-chemotherapy-5-point-score-can-residual-pet-positive-disease-be-cured-with-radiotherapy-alone
#16
Sarah A Milgrom, Chelsea C Pinnix, Hubert Chuang, Yasuhiro Oki, Mani Akhtari, Osama Mawlawi, Naveen Garg, Jillian R Gunther, Jay P Reddy, Grace L Smith, Eric Rohren, Frederick B Hagemeister, Hun J Lee, Luis E Fayad, Wenli Dong, Eleanor M Osborne, Zeinab Abou Yehia, Michelle Fanale, Bouthaina S Dabaja
Early-stage classical Hodgkin lymphoma (HL) patients are evaluated by an end-of-chemotherapy positron emission tomography-computed tomography (eoc-PET-CT) after doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and before radiation therapy (RT). We determined freedom from progression (FFP) in patients treated with ABVD and RT according to the eoc-PET-CT 5-point score (5PS). Secondarily, we assessed whether patients with a positive eoc-PET-CT (5PS of 4-5) can be cured with RT alone. The cohort comprised 174 patients treated for stage I-II HL with ABVD and RT alone...
August 18, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28819821/anti-pd-1-antibodies-as-a-therapeutic-strategy-in-classical-hodgkin-lymphoma
#17
REVIEW
Michael D Jain, John Kuruvilla
Classical Hodgkin lymphoma (cHL) is defined by malignant Reed-Sternberg (RS) cells that recruit non-malignant immune cells into a supportive tumour microenvironment. In cHL, this is driven, in part, by genomic alterations of the 9p24.1 locus encoding the immune checkpoint ligands PD-L1 and PD-L2. Therapeutic anti-PD-1 antibodies have been developed that competitively inhibit the interaction between PD-1 and its ligands. Clinical trials of anti-PD-1 antibodies in cHL demonstrate high overall response rates but relapses still occur and new clinical challenges exist for toxicity management and response assessment...
August 17, 2017: Drugs
https://www.readbyqxmd.com/read/28811872/current-and-emerging-treatment-options-for-mantle-cell-lymphoma
#18
REVIEW
Bita Fakhri, Brad Kahl
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with typically aggressive behavior. The genetic signature is the chromosomal translocation t(11;14)(q13;q32) resulting in overexpression of cyclin D1. Asymptomatic newly diagnosed MCL patients with low tumor burden can be closely observed, deferring therapy to the time of disease progression. Although MCL classically responds to upfront chemotherapy, it remains incurable with standard approaches. For patients in need of frontline therapy, the initial decision is whether to proceed with an intensive treatment strategy or a non-intensive treatment strategy...
August 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/28804091/hodgkin-s-like-lymphoma-in-a-ferret-mustela-putorius-furo
#19
Isao Matsumoto, Kazuyuki Uchida, James Kenn Chambers, Kazumi Nibe, Yu Sato, Taku Hamasu, Hiroyuki Nakayama
A 7-year-old castrated male ferret developed unilateral cervical lymphadenomegaly over a 1-month period. Histological examination revealed proliferation of tumor cells in a diffuse and partially nodular pattern. The tumor cells were predominantly Hodgkin cells and binucleated Reed-Sternberg cells, characterized by abundant, clear, vacuolated cytoplasm, pleomorphic, ovoid nuclei with thick nuclear membranes and distinct nucleoli. Multinucleated cells, resembling lymphocytic and histiocytic (L&H) cells, were also observed...
August 11, 2017: Journal of Veterinary Medical Science
https://www.readbyqxmd.com/read/28798005/hodgkin-s-lymphoma-as-a-multiloculated-lung-cavity-lesion
#20
Aisha M Al-Osail, Hind S Al-Saif, Mashail M Al-Hajri, Hajer M Al-Zuhair, Deemah A Al-Abdulhadi, Emad M Al-Osail, Sarah M Al-Hajri
BACKGROUND: Pulmonary manifestation of Hodgkin's lymphoma is common, and recently, single and/or multiple lung cavities with air-fluid levels has been reported as a primary manifestation of Hodgkin's lymphoma. However, the unusual presentation of the lung cavity itself has not been previously reported for Hodgkin's lymphoma, especially as the first presentation of the disease. CASE PRESENTATION: We report a 16-year-old male who presented to the emergency department with chief complaints of fever, unintentional 10-kilogram weight loss, a productive cough and pulmonary cavity for investigation...
May 2017: Gulf Journal of Oncology
keyword
keyword
49025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"